Pro Medicus Ltd (ASX:PME) has featured among the ASX's most actively traded shares, with the high-flying medical-imaging software company drawing heavy attention even as its share price came under some pressure in September 2026. The Melbourne-based healthcare technology group has been one of the market's standout performers over recent years, winning marquee contracts with leading US health systems for its Visage imaging platform.

Latest Developments

Pro Medicus develops medical imaging and radiology software used by healthcare organisations in Australia, North America and Europe. Its Visage platform is a key part of the company's technology offering. The company has continued to report on financial performance and customer contracts, with long-term agreements remaining an important feature of its business.

What Could Come Next

Catalysts include new contract announcements with US health systems, renewals of existing agreements, and expansion into adjacent products such as artificial-intelligence-enabled tools. Growth in transaction volumes and Margin trends will be key. Management commentary on the sales pipeline and product roadmap will be closely followed.

Risks to Watch

As a high-multiple stock, PME is highly sensitive to any slowdown in contract wins or Earnings growth. Client concentration among large US health systems adds risk, as does competition in medical-imaging software. Regulatory and data-security considerations are important in healthcare technology. Currency movements affect reported results given the significant offshore Revenue base.

Conclusion

Pro Medicus remains one of the ASX's premier healthcare-technology growth stories, combining a proven software platform, high margins and founder-aligned ownership. While recent share-price pressure highlights its premium valuation, the underlying contract-driven growth model continues to attract attention. New contract wins, margin trends and the pace of expansion into AI-enabled products will determine whether PME can sustain its momentum into 2027.